EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer

Zsofia Dora Drobni iD, Carlos Gongora, Jana Taron, Giselle A Suero-Abreu, Julia Karady, Hannah K Gilman, Sama Supraja, Sofia Nikolaidou, Nicolas Leeper, Béla Merkely, Pal Maurovich-Horvat, Borek Foldyna und 1 weitere

Journal for ImmunoTherapy of Cancer · 2023-07 · 11 (7) · e007307

DOI: 10.1136/jitc-2023-007307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 11.07.2023. Verfasst von Zsofia Dora Drobni und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital Department of Radio…. Hauptthemen laut MEDLINE: Atherosclerosis, Lung Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, Hassenfeld Scholar Award, Innovációs és Technológiai Minisztérium.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with lung cancer face a heightened risk of atherosclerosis-related cardiovascular events. Despite the strong scientific rationale, there is currently a lack of clinical evidence examining the impact of immune checkpoint inhibitors (ICIs) on the advancement of atherosclerosis in patients with lung cancer. The objective of our study was to investigate whether there is a correlation between ICIs and the accelerated progression of atherosclerosis among individuals with lung cancer.

Methods

In this case–control (2:1 matched by age and gender) study, total, non-calcified, and calcified plaque volumes were measured in the thoracic aorta using sequential contrast-enhanced chest CT scans. Univariate and multivariate rank-based estimation regression models were developed to estimate the effect of ICI therapy on plaque progression in 40 cases (ICI) and 20 controls (non-ICI).

Results

The patients had a median age of 66 years (IQR: 58–69), with 50% of them being women. At baseline, there were no significant differences in plaque volumes between the groups, and their cardiovascular risk profiles were similar. However, the annual progression rate for non-calcified plaque volume was 7 times higher in the ICI group compared with the controls (11.2% vs 1.6% per year, p=0.001). Conversely, the controls showed a greater progression in calcified plaque volume compared with the ICI group (25% vs 2% per year, p=0.017). In a multivariate model that considered cardiovascular risk factors, the use of an ICI was associated with a more substantial progression of non-calcified plaque volume. Additionally, individuals treated with combination ICI therapy exhibited greater plaque progression.

Conclusions

ICI therapy was associated with more non-calcified plaque progression. These findings underscore the importance of conducting studies aimed at identifying the underlying mechanisms responsible for plaque advancement in patients undergoing ICI treatment. Trial registration number NCT04430712 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisLung NeoplasmsAgedFemaleHumansMaleMiddle AgedCombined Modality TherapyImmune Checkpoint InhibitorsThoraxCase-Control Studies

Stichwörter der Autor:innen

Immune Checkpoint InhibitorsImmunotherapyNon-Small Cell Lung Cancer

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital Department of Radiology, Boston, Massachusetts, USA drobni.zsofia@semmelweis.hu.
  • Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Radiology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany.
  • Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital Department of Radiology, Boston, Massachusetts, USA.

ORCID-Profile: Zsofia Dora Drobni

Förderung

  • NHLBI NIH HHS
  • Hassenfeld Scholar Award
  • Innovációs és Technológiai Minisztérium
  • Deutsche Forschungsgemeinschaft
  • A. Curt Greer and Pamela Kohlberg, the Michael and Kathryn Park Endowed Chair in Cardiology
  • AstraZeneca
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Drobni, Z. D., Gongora, C., Taron, J., Suero-Abreu, G. A., Karady, J., Gilman, H. K., Supraja, S., Nikolaidou, S., Leeper, N., Merkely, B., Maurovich-Horvat, P., Foldyna, B., & Neilan, T. G. (2023). Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer. Journal for ImmunoTherapy of Cancer, 11(7), e007307. https://doi.org/10.1136/jitc-2023-007307

Vancouver

Drobni ZD, Gongora C, Taron J, Suero-Abreu GA, Karady J, Gilman HK, et al. Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer. Journal for ImmunoTherapy of Cancer. 2023;11(7):e007307. doi:10.1136/jitc-2023-007307

BibTeX
@article{Drobni2023,
  author = {Drobni, Zsofia Dora and Gongora, Carlos and Taron, Jana and Suero-Abreu, Giselle A and Karady, Julia and Gilman, Hannah K and Supraja, Sama and Nikolaidou, Sofia and Leeper, Nicolas and Merkely, Béla and Maurovich-Horvat, Pal and Foldyna, Borek and Neilan, Tomas G},
  title = {Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {7},
  pages = {e007307},
  doi = {10.1136/jitc-2023-007307}
}
Kostenlos starten →